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Abstract
Objective—To determine the effectiveness of the Metropolitan Atlanta Community Adolescent 
Rapid Testing Initiative (MACARTI) intervention relative to standard of care (SOC), in achieving 
early diagnosis, linkage and retention among HIV-infected youth ages 18-24 years.
Design—MACARTI was a pilot single-center, prospective, non-randomized study
Methods—MACARTI combined non-traditional venue HIV testing, motivational interviewing 
and case management. We collected demographic, clinical variables and calculated linkage and 
appointment adherence rates. We obtained SOC data from an adolescent HIV clinic. Longitudinal 
data were analyzed using inverse propensity-treatment weighted linear growth models; medians, 
interquartile ranges (IQR), means and 95% confidence intervals (CI) are provided.
Results—MACARTI screened 435 participants and identified 49 (11.3%) HIV infections. The 
SOC arm enrolled 49 new HIV-infected individuals. The 98 participants, (49 in each arm) were: 
85% male; 91% Black; mean age=21 years (SD:1.8). Overall, 63% were linked within three 
months of diagnosis; linkage was higher for MACARTI compared with SOC (96% vs. 57%, 
p<0.001). Median linkage time for MACARTI participants compared to SOC was 0.39 (IQR:
0.20-0.72) vs. 1.77 (IQR:1.12-12.65) months (p<0.001). MACARTI appointment adherence was 
higher than SOC (86.1% vs. 77.2%, p=0.018). In weight-adjusted models, mean CD4+T-cell 
counts increased and mean HIV-1 RNA levels decreased in both arms over 12 months, but the 
differences were more pronounced in the MACARTI arm.
Conclusions—MACARTI successfully identified and linked HIV-infected youth in Atlanta. 
MACARTI may serve as an effective linkage and care model for clinics serving HIV-infected 
youth.
Introduction
Georgia (GA) had the fifth-highest rate of new HIV diagnoses (12.9/100,000) in the United 
States (U.S.) in 2015; 66% of HIV-infected individuals lived in and 69% of new diagnoses 
were reported from Atlanta Metropolitan Statistical Area (Atlanta) in 2011.[1, 2] Gaps along 
the HIV care continuum among youth in Atlanta are evidenced by low rates of testing, 
linkage to care, and viral suppression. Among people living with diagnosed HIV in GA, 
only 68% of youth are linked to care within 30 days, and just 52% and 38% of 13-19 and 
20-24 year olds, respectively, achieved viral suppression at last measurement.[2] 
Additionally, Atlanta youth are likely to be diagnosed at more advanced stages of illness 
with more 13-24 year olds progressing to Stage 2 HIV (CD4 count 200-499) at diagnosis 
compared to any other age group.[3, 4]
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Youth living with HIV have a higher prevalence of psychosocial stressors contributing to 
unfavorable clinical outcomes and broader gaps along the HIV continuum of care compared 
with HIV-infected adults.[5-9] Singer's syndemic theory suggests that healthcare is affected 
by multiple epidemics that should be addressed simultaneously.[10] Adverse social structures 
such as poverty, discrimination, stigma, and psychiatric co-morbidities (including depressive 
disorder, substance use) increase risk for HIV acquisition and adversely impact adherence to 
HIV treatment. [11-13]
Effective interventions tailored to HIV-infected youth are urgently needed. Hall et al. 
showed that only 62% of youth between 13-24 years were linked and 44% retained in care 
nationally.[6] The Reaching for Excellence in Adolescent Care and Health study documented 
that only 32.5% of youth achieved viral suppression,[14] while a Pediatric AIDS Clinical 
Trials Group study demonstrated a 6-month retention rate of 58%.[15] These studies 
underscore deficiencies in traditional approaches of HIV diagnosis and management for 
youth.[16, 17] Newer, comprehensive approaches tailored for youth that address HIV 
diagnosis and management including of psychiatric co-morbidities and psychosocial 
stressors may improve HIV outcomes.
Despite recommendations for routine HIV testing in health-care settings,[16] implementation 
gaps remain; especially in racial/ethnic minority youth.[17] Venue-based HIV testing can 
improve testing rates among youth. A study with young men who have sex with men 
(MSM), showed that factors associated with no previous HIV test included young age (13–
24 years) and identifying as non-Hispanic black or Hispanic.[18] Alternate testing strategies 
have shown high positivity rates among those tested in non-traditional settings.[19]
Motivational interviewing (MI) has been successful in the treatment of chronic 
diseases,;[20, 21] however, data on MI-based interventions in HIV-infected youth are 
limited.[22] A randomized trial in youth assessing the effectiveness of MI delivered either by 
paraprofessional or professional staff showed improved retention in both arms with no 
differences between staff members delivering the intervention. However, pre-intervention 
data were incomplete for the majority of participants.[23] Another study used MI and 
financial incentives with 11 perinatally-infected youth with advanced immunosuppression; 
five achieved viral suppression at one year with a median CD4 count recovery of 140 cells/
μl. This study was limited by small sample size and the potential confounding of financial 
incentives. [24]
Case management (CM) has improved linkage/retention in care of HIV-infected individuals. 
The Antiretroviral Treatment Access Study (ARTAS) randomized recently diagnosed HIV-
infected participants to a brief strength-based model of CM (SBCM) and care planning 
versus usual care; 64% in the intervention arm were linked-to and retained-in care compared 
with 49% in the control arm [RR(adj) 1.41; p=0.006]. ARTAS is recommended as an 
effective intervention by the Centers for Disease Control and Prevention (CDC) [25-27]. 
However, 90% of ARTAS participants were over 26 years of age and youth was 
underrepresented [28].
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Building on these studies, we developed the Metropolitan Atlanta Community Adolescent 
Rapid Testing Initiative (MACARTI) a multi-pronged intervention combining non-
traditional venue HIV testing, MI and CM support to improve diagnosis, linkage and 
retention in care of youth ages 18-24 years. The intervention started with a formative phase 
of focus groups with HIV-infected and uninfected youth to inform a youth-friendly 
strategy.[29, 30] MI/CM approach was implemented through the first year post-diagnosis 
using a developmentally informed approach.
Our goals were to: 1) increase opportunities for HIV testing and diagnosis for youth at 
places where they routinely gather, and 2) strengthen HIV treatment and care for those living 
with HIV using the MACARTI intervention.
Methods
Study Design
MACARTI was a pilot single-center, prospective non-randomized interventional study of 
HIV-infected youth. Enrollment occurred from December 2012 through January 2015, with 
follow-up through February 2016. The MACARTI trial flow (Figure 1) is described briefly 
below. The Emory Institutional Review Board, the Grady Research Oversight Committee, 
and the CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention approved 
this study. All participants provided written informed consent.
Formative Phase and Venue Testing Selection—We conducted focus groups with 68 
HIV-infected and uninfected youth to understand testing preferences and potential venues 
for testing. Seventeen focus groups (11 with HIV-infected, two with HIV-uninfected and 
four with a mixed group of HIV-infected and uninfected youth) were conducted (four 
participants per group). Their responses were used to develop a youth-friendly testing 
strategy, to select testing sites and to better characterize post-diagnosis support. Following 
the focus groups, we conducted ethnographic observations of prospective venues to inform 
site selection.[30] Venues were selected only if they provided a private space for testing.
Testing Phase
Study Team: The MACARTI study staff implementing the intervention included: a 
physician (Study PI-AFCG), a psychology fellow (KF), one case manager, and three 
recruiters/testers. Community partners (AID Atlanta, AIDS Healthcare Foundation and 
Positive Impact) also provided personnel during testing events as needed. Study personnel 
had no previous MI experience and received training by the study psychologist and/or fellow 
(KF or CG), utilizing an MI group facilitator manual with MI information, MI techniques, 
and motivational activities. Study staff learned theoretical and practical applications of MI 
including how to apply reflectively listening and ask open-ended questions, assess levels of 
motivation and confidence, and elicit barriers to adherence, confidence and commitment 
language.[31]
Participants: Participants in the testing phase included youth ages 18-24 years. The 
intervention arm (MACARTI) included youth diagnosed with HIV at non-traditional venues 
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by either the study team or a community partner. The standard of care (SOC) arm included 
participants ages 18-24 years referred to the Ponce Family and Youth Clinic (PFYC) of 
Grady Health Systems for HIV care. Participants from both arms were selected only if they 
had a previously negative or unknown HIV test.
MACARTI arm enrollment procedures: Members of the study team (at least one recruiter 
and one tester) conducted testing in venues selected during the formative phase. For 
participants who agreed to be tested, testing was performed using a sixty-second INSTI™ 
HIV-1/HIV-2 antibody test (BioLytical Laboratories, Inc; sensitivity and specificity of 99.8% 
and 99.5% respectively).[32] The tester conducted an MI/CM session prior to disclosure of 
diagnosis. MI/CM was used prior to disclosure to address potential ambivalence towards 
seeking HIV-related care and to generate a plan of action to either improve clinical outcomes 
(if test was positive) or to establish HIV prevention strategies (if test was negative). HIV-
infected patients were given instructions on how to get to the PFYC and provided 
information about documents needed for enrollment into medical care. After the diagnosis 
was made, study personnel maintained contact and assisted with clinic enrollment. At the 
initial medical visit, each participant had his or her blood drawn for HIV-1 RNA (VL) and 
CD4+T cell (CD4) count. Participants had an MI session with the psychology fellow to 
continue addressing potential ambivalence towards follow-up care with follow-up visits at 1, 
3, 6 and 12 months. All participants received reminder calls the day prior to their study visits 
and for rescheduling purposes if the visit was missed. If participants stopped attending visits 
or answering phone calls from the study team, they were considered lost to follow-up, 
triggering a referral to the health department for tracking purposes. Participants also had the 
option to enroll in another HIV clinic (this was requested by two participants); we then 
helped these participants arrange appropriate follow-up. Participants enrolled at a non-PFYC 
site were asked if they wished to continue in the study. If they did, a signed release of 
medical records was required and the same number of visits occurred with study personnel 
travelling to their preferred clinic to deliver the intervention. No significant differences were 
noted with the delivery of the intervention at the non-PFYC sites.
Standard of Care Participants: SOC participants were newly HIV-diagnosed youth 
referred for care to the PFYC through conventional referrals from other agencies, hospitals 
or medical providers. The PFYC policy is to try to link patients within 72 hours after 
referral; therefore, confounding from the referral process/scheduling was not a concern. 
SOC participants received standard support services upon request including psychological 
and CM support. SOC psychological support met practice standards and CM support was 
limited to providing referrals for housing, food stamps and transportation as needed. SOC 
participants also received reminder calls prior to each appointment for rescheduling 
purposes from PFYC personnel.
Data Collection: Once consented, participants from both arms completed baseline Audio 
Computer-Assisted Self-Interview (ACASI) questionnaires. Data collected included 
demographic information, employment, education, drug use and sexual history. Clinical 
information was obtained from the medical records and included baseline and follow-up 
CD4 count, VL, any antiretroviral therapy (ART) prescriptions, any AIDS-defining 
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diagnoses, and condom use at last sexual encounter. Baseline and follow-up questionnaires 
were obtained at screening, enrollment, at 30 and 90 days, and at six and 12 months.
MACARTI Intervention Components
Motivational Interviewing—A detailed description of the MI component of the 
intervention is presented in Appendix I. Briefly, MI is an evidence-based therapeutic 
approach. Treatment fidelity depends upon the provider's adherence to the “spirit” of the 
approach (namely, partnership, acceptance, compassion and evocation), which can be 
reliably measured (see quality and fidelity section below) as opposed to adherence to 
specific guidelines.[20, 31, 33-35] MI focuses on strengths and self-efficacy, while emphasizing 
collaboration, empowerment, respect for choice, and understanding of the participant's 
perspective.[33] MACARTI participants received MI sessions at the venue before disclosure 
of HIV diagnosis, and at all study visits.
Strength-Based Model of Case Management—An SBCM was employed to empower 
the client, build self-esteem and enable the participants' utilization of available resources. 
This model provides care that is beyond accessing services; it empowers participants to 
identify their own needs in utilizing available resources and services. CM was provided at 
each study visit for the MACARTI arm participants. Problem-solving, goal-planning, and 
guidance counseling were used to help participants with concerns identified by CM. An 
average meeting for CM lasted approximately 45-60 minutes.
Quality and Fidelity—A standard operating procedure manual was developed and 
available to study staff, ensuring quality and fidelity to study procedures. To evaluate fidelity 
to the MI protocol, the MI trainer assessed 20% of the sessions for consistent use of MI 
techniques and re-trained staff if deviations were noted.
Definitions
Linkage to Care—The first medical care visit occurred within 90 days after HIV 
diagnosis.
Retention in care—Number of completed visits divided by the number of total scheduled 
visits during the 12 month follow-up,[36] among participants who attended at least one 
medical care visit. Individuals who never linked (4/98; 4%) were not counted in retention in 
care calculations.
Viral Suppression—The number of participants who had VL <40 copies/ml at the one-
year visit among participants who completed the study.
Statistical Methods
Statistical analyses were performed using SAS v9.4 (Cary, NC) and CRAN R v.3.3 (Vienna, 
Austria), and significance was evaluated two-sided at the 0.05 level. Demographic, drug use, 
sexual history, and clinical characteristics were summarized overall and by SOC and 
MACARTI arms using means and standard deviations, medians and interquartile ranges 
(IQR), or frequencies and percentages as appropriate. Two-sample testing, including both 
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parametric (t-tests and Chi-square tests) and non-parametric (Wilcoxon and Fisher's) 
approaches were used to gauge dissimilarities across the study groups at baseline. 
Differences in visit attendance, retention and linkage between SOC and MACARTI arms 
were similarly considered. Due to noted baseline covariate differences across SOC and 
MACARTI arms, an inverse propensity-treatment weighted (IPTW) score was calculated 
using binary logistic regression and added as an observation weight characteristic to the 
sample, to control for baseline study arm disparities.
Linear mixed-effects growth models were used to evaluate statistical differences over study 
visit follow-up in CD4 count and VL between the SOC and MACARTI arms. The fixed 
effect for each model was treatment arm (2 levels), and the random effects were participant-
specific intercepts and study visit slopes. Interactions between treatment arm and study visit 
were included, and due to curve-linear associations in the raw data, quadratic terms were 
added to each model for study visit. For CD4 count, a square-root transformation was 
applied to the outcome; for VL, both the outcome values and study visit were natural-log 
transformed. All observations in the mixed-effects regression models were evaluated 
unweighted and weighted using the IPTW score. All presented results have been back-
transformed to their original units, and results are given as least-squares mean estimates with 
associated 95% confidence intervals (CI). Further details for the propensity and linear 
growth models are provided in Appendix II.
Results
We tested 435 participants and identified 49 as HIV-infected, for a positivity rate of 11.3%. 
Multiple sites were used for testing, however the highest positivity rate was seen in 
nightclubs (30%) and street testing in areas identified as high risk by ethnographic studies 
(18%) (Table 1). The SOC arm screened 62 participants to enroll 49 HIV-infected 
individuals new to HIV care; thirteen were excluded because they were not new to HIV care. 
Ninety-eight participants, 49 in each arm, were enrolled; 85% male; 91% Black; mean age 
was 21 years (SD: 1.8 years); 78% identified as homosexual/bisexual or queer; 62% had 
high school education or less; 23% percent reported currently using drugs (marijuana, 
cocaine, heroin, methamphetamines, ecstasy, inhalant or other); 14% reported a history of 
abuse (Table 2). After IPTW-adjustment, all differences were balanced between MACARTI 
arm and SOC participants (Table 2), per a weighted standardized difference cutoff of 0.25.
Baseline HIV characteristics
Compared with SOC, MACARTI arm participants reported fewer AIDS-defining conditions 
(20% vs 51%, p=0.002) and a higher mean CD4 count (317 (IQR: 218-512) vs. 196.5 (IQR: 
61-377.5) cells/mm3, p=0.007).
Linkage to Care
Overall, 63% of participants were linked to care within 90 days of diagnosis; however, 
linkage was higher for the MACARTI arm compared with SOC (88% vs. 39%, p<0.001). 
Weighted, MACARTI linkage remained higher than SOC (96% vs 57%, p<0.001). Weighted 
median linkage time for MACARTI participants compared to SOC was 0.39 (IQR: 
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0.20-0.72) vs. 1.77 (IQR: 1.12-12.65) months (p<0.001). An IPTW-adjusted multivariable 
logistic model showed that MACARTI participants had significantly higher odds of linking 
within 90 days than those in SOC arm (aOR= 18.17, 95% CI: 3.27-100.90).
Retention in Care
MACARTI arm participants had better appointment adherence compared to SOC 
participants (86.1% vs. 77.2%, p=0.018). MACARTI participants also had better adherence 
throughout each of the follow-up study visits, albeit only significant at 90 days (Table 3). We 
also looked at the percentage of participants who attended 80 and 100% of clinical visits 
scheduled. Although there was no statistical difference at 80% of scheduled visits, 50% of 
MACARTI participants attended 100% of the visits compared to 26% in the SOC arm 
(p=0.017).
CD4 Count and HIV-1 RNA Levels
CD4 counts increased significantly within both arms. Growth model estimates indicated 
MACARTI and SOC participants gained 149 cell/mm3 and 101 cells/mm3, respectively, at 
12 months. Additionally, CD4 counts in the MACARTI arm were significantly higher at all 
study visits relative to the SOC arm ( Appendix II-Table 3b). The growth trajectory in CD4 
count over participant follow-up was significantly higher in the MACARTI arm relative to 
the SOC (p=0.004) (Figure 2; Appendix II-Table 3a). Growth model estimates for VL 
indicated significant decreases in both arms, and although the overall growth trajectories 
were not significantly different between the two arms (p=0.1) (Figure 2; Appendix II-Table 
4a), MACARTI arm participants had significantly lower VL at six months (p=0.031) and 
one year (p=0.008), respectively ( Appendix II-Table 4b). At one year, the weighted 
percentage of participants in the MACARTI arm who had an undetectable VL was 83% 
compared to 41% in SOC arm (p<0.001); concurrently, the odds of having an undetectable 
VL at one year was significantly higher in MACARTI compared to the SOC arm (aOR= 
6.80, 95% CI: 2.09-22.15, p=0.002).
Discussion
The MACARTI intervention successfully identified HIV-infected youth in the community, 
linking them to HIV care within 90 days of diagnosis and achieving high retention rates 
consistent with National HIV/AIDS Strategy goals.[37] Factors such as psychological 
distress, fear, lack of information, traumatic experiences, and lack of food, transport and 
housing, create syndemics of risk and add complexity to the care of HIV-infected youth.[38] 
MACARTI utilized MI and CM to address behavioral, motivational, and socioeconomic 
factors that affect HIV care. In MACARTI, MI started in the venue prior to disclosure of the 
diagnosis to build rapport, prepare participants emotionally in the event of a positive HIV 
test, and to enable participants to develop a plan of action proactively, regardless of the test 
result. After linkage, MI promoted achievement of: 1) attending medical visits, 2) initiating 
and adhering to ART, and 3) achieving viral suppression.
MACARTI identified high-risk youth, validating our formative work and targeted testing 
strategy. Strategies designed without youth input may not be able to access this hard-to-
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reach population, underscoring the importance of developing youth-oriented, culturally-
competent interventions. MACARTI also enabled diagnosing youth at earlier stages of HIV 
disease compared to participants in the SOC arm. Early diagnosis and treatment of HIV has 
significant individual and public health advantages, including increased survival and 
decreased secondary transmission.[39, 40] Interventions incorporating enhanced testing, 
linkage, and retention components can reduce HIV incidence by 54% and mortality rate by 
64%; these outcomes are cost-effective compared to no intervention.[41]
Although MACARTI was not powered to look at differences in HIV clinical parameters, we 
noted decreases in VL and increases in CD4 count in both arms. The CD4 count trend over 
time was significantly better for the MACARTI than the SOC arm participants. VL was 
lower at all time points for MACARTI arm participants, however, statistical significance was 
reached during the latter part of the follow-up period suggesting that youth-informed 
interventions, such as MACARTI, provide additional support time-points beyond the first 
few months post-diagnosis. This type of intervention may seem more labor intensive and 
challenging for broader implementation purposes; however, the psychosocial needs of youth 
may require such interventions in order to achieve the desired HIV continuum of care goals 
in this population.
This study has several limitations. First, the study population reflected a convenience sample 
that was not identified randomly, and the study was conducted in a single site. Although 
results may not be generalizable, the HIV epidemiology in GA reflects the current US 
epidemic. [1] Additionally, since the PFYC is the only adolescent HIV clinic in GA, we 
potentially accessed the majority of HIV-infected youth in Atlanta. Second, several 
differences in baseline characteristics were noted between groups. Some of these differences 
may be related to the venue selection process (not all potential venues where chosen as we 
required specific standards for testing confidentially and privacy), which may have shifted 
the MACARTI population towards a more employed/educated population that could afford 
entrance to specific sites. Additionally, since the intervention included targeted testing based 
on our formative phase results and positivity rates obtained in the different venues, we could 
have inadvertently oversampled the gay/bisexual population. However, the use of IPTW 
balanced both groups, which allowed us to control for differences in baseline characteristics 
during the analysis. Third, for the linear growth models, missing data were handled under a 
mixed-model framework, allowing for incomplete observations in the analysis. For all other 
analyses, complete case data were used, and missing observations were removed. 
Concurrent with the mixed-model framework, missing data were assumed to be at random 
after visual evaluation of the participation logs for patterns in attrition, as well as 
quantitative analyses considering univariate differences in the baseline covariates between 
those that attended their study visits versus those that did not. While we feel missing at 
random is an appropriate assumption for our data, we acknowledge that some missing data 
may not be random. Fourth, although we found significant differences in CD4 count and VL 
trends, which suggests improved immunologic recovery and viral control in the MACARTI 
arm, our sample sizes were small; larger studies are warranted to confirm this finding.
In conclusion, despite the need of a larger randomized control study to further test this 
intervention, the results of the MACARTI trial are very promising and suggest that the 
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combination of non-traditional venue testing, MI and CM has the potential to effectively 
decrease gaps for youth along the HIV care continuum.
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Figure 1. The MACARTI Trial Flow Diagram
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Figure 2. Model-based change in CD4 count and viral load overtime by treatment arm – Mean 
estimates and 95% confidence intervals, The MACARTI Trial, Atlanta, GA 2012-2016
Camacho-Gonzalez et al. Page 14

























Camacho-Gonzalez et al. Page 15
Table 1
Testing Venues and Positivity Rate The MACARTI Trial, Atlanta, GA 2012-2016
Venue Type Number Tested Identified Positives Positivity Rate
Night Clubs 122 37 30%
College Campus 98 5 5%
Street Testing1 38 7 18%
Private Parties 19 0 0%
Pride Events 38 0 0%
Malls and surroundings 6 0 0%
Fairs 19 0 0%
Shelters 95 0 0%
Total 435 49
1
Previously determined high risk areas by ethnographic studies
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Table 3
Proportion of appointment adherence stratified by study arm, The MACARTI Trial, 
Atlanta, GA 2012-2016




30 Days 35/49 (71.4%) 38/45 (84.4%) 0.130
90 Days 37/49 (75.5%) 43/45 (95.6%) 0.008
6 Months 30/49 (61.2%) 34/45 (75.6%) 0.137
12 Months 30/49 (61.2%) 33/45 (73.3%) 0.212
Overall 181/245 (73.9%) 197/229 (86%) 0.001
Weighted
30 Days 42.6/52.7 (80.8%) 30/37.8 (79.3%) 0.864
90 Days 36.8/52.7 (69.9%) 36.1/37.8 (95.6%) 0.002
6 Months 32.4/52.7 (61.5%) 29.1/37.8 (77%) 0.119
12 Months 39/52.7 (74%) 29.8/37.8 (78.8%) 0.603
Overall 203.6/263.6 (77.2%) 162.7/188.9 (86.1%) 0.018
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